JCO Global Oncology最新文献

{"title":"Pilot Study Assessing Stigma in Kenyan Women With Breast Cancer.","authors":"Mansoor N Saleh, Kevin Owuor, Anna Helova, Sehrish Rupani, Karishma Sharma, Noureen Karimi, Isaiah Omedeo, Stacey Gondi, Divya Annamalai, Lily Gutnik, Innocent Abayo, Janet M Turan","doi":"10.1200/GO-24-00479","DOIUrl":"https://doi.org/10.1200/GO-24-00479","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is the most common female cancer in Kenya, frequently presenting at late stage, and associated with high mortality. The stigma around cancer has been identified as a barrier to early detection and treatment in many settings globally. This pilot study investigated associations between breast cancer stigma, depression, anxiety, and health-related quality of life (HRQOL) outcomes.</p><p><strong>Methods: </strong>A cross-sectional survey of 60 participants (30 newly diagnosed breast cancer [NDBC] and 30 previously treated breast cancer [PTBC]) was conducted at Aga Khan University Hospital, Nairobi, Kenya. Validated survey measures included a chronic illness stigma scale adapted for breast cancer, depression, anxiety, and HRQOL. Penalized logistic and linear regression analyses were also performed.</p><p><strong>Results: </strong>The participants' mean age was 49.9 years (±12.1). A quarter (25%) of the participants experienced anxiety, whereas 13.3% showed signs of depression, with a mean HRQOL score of 79 (±16.9). The mean breast cancer stigma score was 39.8 (±14.9). The adjusted predicted probability of depression increased as the stigma score increased and was higher among PTBC participants than NDBC participants. The adjusted predicted probability of anxiety also increased as the stigma scores increased and was higher among those who had NDBC than PTBC participants. The adjusted predicted change in the log of HRQOL decreased as the stigma score increased and was higher among NDBC participants than PTBC participants at diagnosis.</p><p><strong>Conclusion: </strong>Among women diagnosed with breast cancer, this study highlights the association of increased breast cancer-related stigma with anxiety, depression, and lower QOL.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400479"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastasis-Directed Stereotactic Body Radiation Therapy in Oligometastatic and Oligoprogressive Solid Malignancy: Outcomes and Effect on Systemic Treatment.","authors":"Abdulla Alzibdeh, Lina Wahbeh, Shatha Abu Taha, Mohamed Qambar, Abdelatif Al Mousa, Jamal Khader, Fawzi Abuhijla, Ayah Erjan, Anoud Alnsour, Issa Mohamad, Baha Sharaf, Soha Ahmed, Sara Mheid, Hikmat Abdel-Razeq, Wafa Asha","doi":"10.1200/GO-25-00004","DOIUrl":"https://doi.org/10.1200/GO-25-00004","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the clinical outcomes and evaluate Freedom from Introduction or Switching of Systemic Treatment (FISST) in patients with oligometastatic (OM) and oligoprogressive (OP) disease undergoing stereotactic body radiotherapy (SBRT).</p><p><strong>Methods: </strong>The primary end points were FISST and local control (LC) rates of lesions that received SBRT. The secondary end point was overall survival (OS) after SBRT. To calculate FISST, event was defined as the need to introduce or switch the systemic line of treatment for any reason or inability to provide systemic treatment when needed because of poor performance status (PS) (Eastern Cooperative Oncology Group PS ≥3) or other reasons. OS was a secondary outcome.</p><p><strong>Results: </strong>A total of 200 patients were included. The median age was 60 (IQR, 49-70) years. The most common primary tumors were colorectal (61, 30.5%), breast (30, 15.0%), lung (28, 14.0%), head and neck (23, 11.5%), and prostate (16, 8.0%). A total of 257 metastatic lesions were treated. Bone was the most frequent site (115, 44.7%), followed by the liver (55, 21.4%), lung (44, 17.1%), lymph nodes (25, 9.7%), and adrenal glands (11, 4.3%). The median follow-up was 15 months. FISST at 1 and 2 years were 52% and 39%, respectively. LC at 1 and 2 years were 86.3% and 80%, respectively. OS at 1 and 2 years were 76.5% and 64.8%, respectively. Grade III toxicity was reported in 1.5% of patients overall, with no observed grade IV or V toxicity.</p><p><strong>Conclusion: </strong>SBRT is effective and safe for treating OM and OP solid cancers, prolonging FISST and potentially delaying systemic treatments, particularly in settings with limited access to advanced therapies.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500004"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of All Solid Tumor Drug Approvals From 2019 to 2024 by US Food and Drug Administration, European Medicines Agency, and Brazilian Health Regulatory Agency.","authors":"Rafael Balsini Barreto, Mário Henrique Furlanetto Miranda, Camila Marchi Blatt, Bárbara Andressa Uliana, Denize Bodnar","doi":"10.1200/GO-25-00326","DOIUrl":"https://doi.org/10.1200/GO-25-00326","url":null,"abstract":"<p><strong>Purpose: </strong>Regulatory agencies play a pivotal role in evaluating clinical evidence for oncology drug approvals. This study aimed to compare approved indications across the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Brazilian Health Regulatory Agency (ANVISA), with a focus on the robustness of the supporting evidence and consistency between labeling and clinical trial data.</p><p><strong>Methods: </strong>A systematic review identified all new drugs and indications for solid tumors approved by the FDA from January 1, 2019, to December 31, 2024. Each approval was cross-referenced with corresponding decisions by EMA and ANVISA. For each indication, the pivotal trial's design, primary end point, study population, and the concordance between the approved label and the clinical evidence were identified.</p><p><strong>Results: </strong>During the 6-year period, 199 new indications for solid tumors were approved by the FDA; 138 (69.3%) were also approved by EMA and 124 (62.3%) by ANVISA. Discrepancies between approved labels and the primary end point population occurred in 10.0% of FDA, 18.8% of EMA, and 12.9% of ANVISA approvals, most often due to label restrictions to subgroups, indicating a more conservative approach by EMA and ANVISA. Labeling differences were noted in 19 of 139 FDA-EMA and 10 of 124 FDA-ANVISA shared approvals. A total of 190 pivotal trials supported these approvals, including three phase I, 59 phase II, and 128 phase III studies. The most frequent end points were overall response rate and progression-free survival, including in phase III trials and regular approvals, rather than overall survival or quality of life.</p><p><strong>Conclusion: </strong>Notable differences in timelines, regulatory mechanisms, and evidentiary thresholds across agencies result in divergent labeling. These variations have clinical and pol<u>i</u>cy implications for oncology drug access and adoption worldwide.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500326"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145300681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual Fronts: The Psychological and Logistical Burden of War on Oncology Patients.","authors":"Sagar Raut","doi":"10.1200/GO-25-00256","DOIUrl":"https://doi.org/10.1200/GO-25-00256","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500256"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145300702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Translational Considerations for Global Health Settings: Portable Detection of Human Papillomavirus for Cervical Cancer Screening in India.","authors":"Vi T Nguyen, Siril Arockiam, Pankaj Kumar, Joshua Eger, Kirk Herman, Shachi Vashist, Neerja Bhatla, Lalit Dar, Dean E Brenner, Karen S Anderson, Jennifer Blain Christen","doi":"10.1200/GO-25-00117","DOIUrl":"https://doi.org/10.1200/GO-25-00117","url":null,"abstract":"<p><strong>Purpose: </strong>Translation of diagnostic technology developed at the laboratory bench involves iterations of user feedback and design modifications. Learning about translational requirements early in the design process facilitates the development of feasible prototypes that have a better likelihood of implementation in global health settings. During our development of a portable system to detect human papillomavirus (HPV) for cervical cancer screening in India, we encountered and solved issues related to research translation. We report our findings to help others deploying diagnostic technology for global health.</p><p><strong>Materials and methods: </strong>We designed a point-of-care system to process patient samples and diagnose HPV infection in the cervix. We continually shipped components of the system from the United States to our collaborating team in India to assess component condition and usability at the local site. We simultaneously developed HPV isothermal amplification assays that were fit for purpose. Cervical brush samples were used in our portable system for functional validation.</p><p><strong>Results: </strong>We found ideal transport methods to ensure component quality and reagent stability through the international shipment chain. Portable systems should be designed as simple as possible for correct usage at the local testing site. Usability tests drove our design improvements from 28% to 93% success rates. We demonstrated proof-of-concept functionality of our portable system for 13 cervical brush samples on-site, with a sensitivity of 100% and specificity of 88.9%.</p><p><strong>Conclusion: </strong>Issues related to technology transfer for global health settings manifest during distribution and deployment of prototypes. We identified several issues during our synergistic design process and report recommendations on the basis of our experience.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500117"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral T-Cell Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.","authors":"Jason Yongsheng Chan, Ayumi Fujimoto, Esther Wei Yin Chang, Gin Gin Gan, Sen Mui Tan, Soo Chin Ng, Kian Meng Chang, Priscilla Caguioa, Jay Datukan, Huangming Hong, Suporn Chuncharunee, Do Huyen Nga, Noorwati Sutandyo, Choon Kiat Ong, Michelle Limei Poon, Anand Jeyasekharan, Nagavalli Somasundaram, Matthew Lunning, Ritsuro Suzuki, Koji Izutsu, Eric Tse, Soon Thye Lim, Won Seog Kim","doi":"10.1200/GO-25-00353","DOIUrl":"https://doi.org/10.1200/GO-25-00353","url":null,"abstract":"<p><strong>Purpose: </strong>Peripheral T-cell lymphomas (PTCLs) encompass a group of rare and diverse disease entities for which contemporary frontline treatment options are limited. Patient outcomes for PTCL remain poor globally, and disparities in health care resources and health care system variability across East and Southeast Asia (hereafter referred to as Asia) further complicate PTCL management in the region. This article reviews the practice landscape for PTCL in Asia, provides a nuanced perspective on the challenges faced by physicians in the region, and suggests how patient outcomes can be improved.</p><p><strong>Methods: </strong>A panel of lymphoma experts from 10 countries/territories across Asia convened at the Singapore Lymphoma Scientific Symposium 2024 to discuss local PTCL management practices. Discussions were supplemented by perspectives from an expert from the United States and a review of published literature on PTCL in Asia in the past 10 years. Meeting discussions and relevant aspects of Asian PTCL practice preferences are summarized in this article.</p><p><strong>Results: </strong>In Asia, PTCL diagnosis and management are hindered by the lack of available domain experts, limitations in infrastructure support and funding, and substantial challenges in accessing novel drugs; relapsed/refractory PTCL, in particular, remains an area of great clinical unmet need. To improve the standard of care for patients with PTCL, cross-country collaborative efforts will be required to facilitate cross-border knowledge sharing, enhance access to expertise and specialized pathology services, increase local clinical trial presence, and offer educational and research opportunities.</p><p><strong>Conclusion: </strong>Significant challenges remain for PTCL management in Asia. Concerted efforts to enhance diagnostic accuracy, improve access to innovative therapies, and establish robust international partnerships are crucial for achieving better outcomes for patients with PTCL in the region.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500353"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between the Test-and-Treat Strategy and the Severity of Cervical Dysplastic Lesions Among Women Living With HIV in Tanzania (2015-2023).","authors":"Pooja S Yerram, Chacha Josiah Mwita, Julius Mwaiselage, Batya Elul, Amr S Soliman","doi":"10.1200/GO-24-00540","DOIUrl":"10.1200/GO-24-00540","url":null,"abstract":"<p><strong>Purpose: </strong>Cervical cancer remains a leading cause of morbidity and mortality in Tanzania where HIV exacerbates the risk of cancer and dysplasia. In 2017, Tanzania adopted the Test-and-Treat program for patients with HIV, which mandates immediate antiretroviral therapy for people living with HIV, regardless of CD4 count. This study examined the impact of this strategy on the severity of cervical dysplasia among women living with HIV (WLWH) at the Ocean Road Cancer Institute (ORCI).</p><p><strong>Methods: </strong>We used existing data of women who came to the ORCI cervical cancer early detection clinic between 2015 and 2023 for cervical cancer early detection. Of the 3,385 women screened, 1,686 were diagnosed with dysplastic lesions and included in the analysis. This subset consisted of 349 WLWH, 605 HIV-negative women, and 732 women with unknown HIV status. The remaining women either were visual inspection with acetic acid-negative or had suspected cervical cancer and were not included in the final analysis of dysplastic lesions. The year 2017 was chosen as a pivotal point for analysis because it marked the implementation of the Test-and-Treat strategy at the ORCI. The severity of dysplasia before and after 2017 was compared using trend and logistic regression analyses.</p><p><strong>Results: </strong>The Test-and-Treat strategy was associated with a significant increase in detecting small/moderate lesions (<i>P</i> < .0001). The odds of being diagnosed with small/moderate lesions versus large lesions were approximately four times higher post-2017 (odds ratio, 3.972 [95% CI, 2.462 to 6.409]).</p><p><strong>Conclusion: </strong>The Test-and-Treat strategy has significantly reduced the severity of cervical dysplasia among WLWH at the ORCI, highlighting the importance of integrating HIV treatment into cervical cancer prevention programs. Continuous research focusing on the long-term effects of the Test-and-Treat strategy and expansion of on-site pathology services, including timely histopathologic diagnosis, are essential to further reduce cervical cancer incidence, morbidity, and mortality among WLWH.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400540"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12532265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145300678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lessons Learned From 7 Years of Implementing Cervical Cancer Screening and Treatment in Equatorial Guinea.","authors":"Beulah Jayakumar, Antonio Ngua Roca, Liyu Teklemichael, Manuel Ondo Oyono, Florentino Abaga Ondo Ndoho, Josefa Nsa Mangue, Anastasia Mazig, Carolina Amadu Muana, Jose Avelino Rondo Massoko, Diana Espitia, Pilar Batapa Beaka, Jordan M Smith, Catherine Sanders, Wonder P Phiri, Guillermo A García, Sandra Incardona","doi":"10.1200/GO-24-00658","DOIUrl":"https://doi.org/10.1200/GO-24-00658","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the results of the Cervical Cancer Screening and Treatment (CCST) project in Equatorial Guinea and the reach of facility-based and community outreach service delivery strategies.</p><p><strong>Materials and methods: </strong>The CCST project implemented the single-visit, screen-and-treat approach, using visual inspection with acetic acid (VIA) and treatment with cold coagulation (and referral for further evaluation where needed) for women age 20-60 years. The project deployed two service delivery strategies: in health facilities and through community outreach. The project conducted cascaded training, routine supervision for quality improvement, communication campaigns, and community mobilization efforts.</p><p><strong>Results: </strong>Between 2017 and 2023, 26,998 women were screened. The two strategies reached almost equal numbers of women. Community outreach reached more women in the country's mainland. It also reached significantly more married women, women with age at first sexual intercourse at or before 16 years, and those who were puerperal, postmenopausal, and multiparous than facility-based screening. VIA positivity rate was 2.6% overall, with higher rates among younger women. Fifty-five percent of VIA-positive women were treated with cold coagulation, 10% were referred for further evaluation, and 18% received no treatment.</p><p><strong>Conclusion: </strong>To our knowledge, this first-ever effort in CCST in Equatorial Guinea has shown that both facility-based and community outreach are effective in implementing the single-visit, screen-and-treat approach and underscores the need to continue and further expand the effort, strengthen the quality of services delivered and data capture, and increasingly transfer the capacity to implement facility-based screening and community outreach to the Ministry of Health.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400658"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Waiting Time and Treatment Duration on Short-Term Outcomes for Patients With Locally Advanced Cervical Cancer at the Uganda Cancer Institute: The Challenges in Resource-Limited Settings.","authors":"Awusi Kavuma, Solomon Kibudde, Daniel Mukasa Kanyike, Israel Luutu, Jackson Orem","doi":"10.1200/GO-25-00325","DOIUrl":"https://doi.org/10.1200/GO-25-00325","url":null,"abstract":"<p><strong>Purpose: </strong>Cervical cancer remains a significant public health burden, especially in sub-Saharan Africa. The waiting time and treatment duration are key indicators of quality in oncology care, and guidelines recommend that chemoradiation for patients with locally advanced cervical cancer (LACC) should be completed within 8 weeks. This study aimed to quantify waiting times and treatment durations for LACC at the Uganda Cancer Institute and identify bottlenecks in the radiotherapy treatment pathway.</p><p><strong>Materials and methods: </strong>This prospective study involved 196 patients with LACC. The department's treatment protocol for LACC allows either conventional fractionated radiotherapy (CFRT) at 50 Gy/25# or hypofractionated radiotherapy (HFRT) at 45 Gy/15#, followed by brachytherapy at 24 Gy/3#. Nine key treatment milestones were documented from diagnosis to brachytherapy completion. The impact of social determinants of health on waiting times was analyzed. Responses were assessed 6 months after treatment completion.</p><p><strong>Results: </strong>Patients spent a median delay time of 41 days and a median waiting time of 88 days. The median external beam radiation therapy duration was 40 days for CFRT, compared with 24 days for HFRT. The median waiting time before initiating brachytherapy was 40 days, leading to an overall treatment duration of 85 days for CFRT and 66 days for HFRT. Only 18% of patients on CFRT and 37% of patients on HFRT completed within timelines. The proportions of patients with either waiting times or treatment duration of ≤8 weeks who had complete responses were comparatively greater than those who started treatments after >8 weeks.</p><p><strong>Conclusion: </strong>Only 25% completed treatment within the recommended timelines. The long waiting time for brachytherapy makes it impossible to finish within timelines. Strategies to expedite access to brachytherapy are necessary to enhance radiotherapy quality.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500325"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145251102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Burden of Thyroid Cancer in Adults Age 15-49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021.","authors":"Min Zhang, Min Zhao, Yang Li, Meimei Cui, Jiayi Chen, Jingjing Jia, Wenjie Yan, Limei Luo","doi":"10.1200/GO-25-00185","DOIUrl":"https://doi.org/10.1200/GO-25-00185","url":null,"abstract":"<p><strong>Purpose: </strong>This study used the latest data from the Global Burden of Disease (GBD) 2021 to comprehensively analyze the burden of thyroid cancer in adults age 15-49 years globally.</p><p><strong>Methods: </strong>Data from the GBD 2021 were used. The estimated annual percentage changes (EAPCs) were used to assess the trends in thyroid cancer. Decomposition analysis was used to identify the factors contributing to the observed epidemiological changes in thyroid cancer. Projections of the thyroid cancer burden through 2044 were generated using the Nordpred modeling.</p><p><strong>Results: </strong>In 2021, there were 96,287.8 thyroid cancer cases in adults globally. From 1990 to 2021, the age-standardized incidence rate (ASIR; EAPC = 1.68; 95% uncertainty interval [UI], 1.56 to 1.81) and the age-standardized disability-adjusted life year (DALY) rate (EAPC = 0.21; 95% UI, 0.18 to 0.23) of thyroid cancer in adults showed an increasing trend, whereas the age-standardized mortality rate (EAPC = -0.03; 95% UI, -0.05 to -0.01) showed a downward trend. Females showed an upward trend only in ASIR, whereas males were on the rise in all trends of age-standardized rates from 1990 to 2021 globally. Decomposition analysis revealed that the population growth was a major contributor to the deaths and DALYs associated with thyroid cancer. By 2044, thyroid cancer incidence, deaths, and DALYs are projected to reach 121,096, 6,293, and 384,836, respectively.</p><p><strong>Conclusion: </strong>Thyroid cancer, particularly among adults, has emerged as a global health concern. Our findings suggest that targeted strategies and measures are urgently needed for the prevention and management of thyroid cancer in adults, especially among males.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500185"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}